Rosen Quoted on FDA Warning Letters Issued to Drug Compounders

31 January 2014 Inside Health Policy News

Inside Health Policy

Partner David Rosen was quoted in an Inside Health Policy article on January 31, 2014 titled, “First DQSA Warning Letters Target Compounders Without Prescriptions.” The article discusses the two warning letters issued by the FDA to drug compounders in recent weeks chastising them for lacking patient-specific prescriptions. Rosen was quoted saying, “If you do not have an individual prescription for every patient for whom you compound, this is one way FDA is sending the message that you are not compliant with 503A at this time.”

Related Services

Insights

CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments
20 November 2019
Health Care Law Today
The Purpose of a Corporation
November 2019
Legal News: Business Law
Should This Be a "Mobility" Industry Blog?
19 November 2019
Dashboard Insights
Data Processing Patent Eligibility: Federal Circuit Finds Claims Eligible in KPN v. Gemalto
19 November 2019
IP Litigation Current
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
HFMA MA-RI Annual Compliance Update
12 December 2019
Boston, MA